4/30
07:42 am
tenx
Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) [Yahoo! Finance]
Low
Report
Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) [Yahoo! Finance]
4/30
07:30 am
tenx
Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Low
Report
Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
4/9
08:37 am
tenx
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study” [Yahoo! Finance]
Medium
Report
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study” [Yahoo! Finance]
4/9
08:30 am
tenx
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”
Low
Report
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”
3/28
08:40 am
tenx
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results [Yahoo! Finance]
Medium
Report
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results [Yahoo! Finance]
3/28
08:30 am
tenx
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
Medium
Report
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
3/12
08:52 am
tenx
Tenax Therapeutics to Present at the 36th Annual Roth Conference [Yahoo! Finance]
Neutral
Report
Tenax Therapeutics to Present at the 36th Annual Roth Conference [Yahoo! Finance]
3/12
08:30 am
tenx
Tenax Therapeutics to Present at the 36th Annual Roth Conference
Low
Report
Tenax Therapeutics to Present at the 36th Annual Roth Conference
2/29
09:19 am
tenx
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024 [Yahoo! Finance]
Medium
Report
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024 [Yahoo! Finance]
2/29
09:00 am
tenx
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024
Medium
Report
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024
2/20
12:10 pm
tenx
Tenax Therapeutics, Inc. (NASDAQ: TENX) had its "buy" rating re-affirmed by analysts at Roth Mkm. They now have a $30.00 price target on the stock.
Low
Report
Tenax Therapeutics, Inc. (NASDAQ: TENX) had its "buy" rating re-affirmed by analysts at Roth Mkm. They now have a $30.00 price target on the stock.
2/20
08:38 am
tenx
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan [Yahoo! Finance]
Medium
Report
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan [Yahoo! Finance]
2/20
08:30 am
tenx
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan
High
Report
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan
2/8
08:21 am
tenx
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering [Yahoo! Finance]
Low
Report
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering [Yahoo! Finance]
2/8
08:16 am
tenx
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering
High
Report
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering
2/7
08:11 pm
tenx
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF) [Yahoo! Finance]
High
Report
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF) [Yahoo! Finance]
2/7
08:01 pm
tenx
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
High
Report
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)